Navigation Links
Cytopia Commences Phase II Cancer Drug Study
Date:12/17/2007

Cytopia's first Phase II clinical trial

MELBOURNE, Australia, Dec. 18 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has obtained regulatory approval to proceed with a Phase II clinical study assessing its lead anti-cancer drug in up to 24 multiple myeloma patients. Patient enrolment will soon commence.

This Phase II study is the first in a number of further clinical studies planned for the anti-cancer vascular-disrupting agent CYT997 and will be conducted at the Alfred Hospital in Melbourne, Australia. It will investigate the activity of CYT997 in patients with relapsed or refractory multiple myeloma.

Multiple myeloma is an incurable cancer of plasma cells of the bone marrow, where the cells divide in an uncontrolled manner invading not only the marrow but the solid bone tissue. The human clinical trial follows promising laboratory studies which indicate that CYT997 potently disrupts myeloma cells, including those collected from patients with the disease.

While some significant advances in myeloma therapy have occurred in recent years, disease recurrence almost always occurs with increasing drug resistance leading to uncontrollable and fatal disease.

To be eligible for the study, patients must have failed at least one previous line of approved therapy. The trial is a single-arm, two-stage design with an interim analysis after 14 patients and maximum enrolment of 24 subjects. The company anticipates releasing interim data for this study in the third quarter of 2008.

"We are keen to unlock the potential of CYT997 as a next-generation cancer drug, particularly in indications with unmet medical need," said Mr Andrew Macdonald, CEO of Cytopia. "This study is the first of Cytopia's planned suite of Phase II studies for CYT997 and is a substantial value-adding milestone for the company."

The market for multiple myeloma drugs was estimated at US$930 million in 2006 and is expected to grow to approximately US$3 billion by 2013.

Cytopia is also currently conducting a Phase I study investigating the safety and tolerability of CYT997 following oral administration. The company also intends to file regulatory applications in support of other Phase II studies over the coming months.

The following table provides a summary of the key aspects of the Phase II multiple myeloma trial.

Name of trial A prospective, single-arm, two-stage, open-label

Phase II trial of CYT997 in relapsed and

refractory multiple myeloma (CCL07001)

Primary endpoints Determination of the overall response rate to CYT997

Secondary endpoints Time to progression; number of cycles of CYT997 to

achieve maximum response; overall survival and

safety and tolerability

Blinding status Not blinded

Product development Drug substance and drug product are manufactured to

status GMP standards

Treatment method

Route 24 hour intravenous infusion dose

Frequency Days 1 and 8 of a 21 day cycle

Dose-levels 202 mg/m2 CYT997 dihydrochloride

Number of trial 24 patients maximum

subjects

Subject selection Eligible patients must have a diagnosis of

criteria multiple myeloma (per World Health Organisation

criteria) and have received at least one but no

more than three previous lines of therapy

Trial location Melbourne, Australia

Expected completion Interim analysis (14 patients) Q3, 2008

Trial standard ICH-GCP

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Exelixis Commences Public Offering of Common Stock
3. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
4. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
5. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
6. Ovation further advances development pipeline with new phase III epilepsy study
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Manic phase of bipolar disorder benefits from breast cancer medication
11. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Peachtree City, GA (PRWEB) , ... February 08, 2016 , ... ... healthy and cavity-free. February is National Children’s Dental Health Month and family dentist Yvonne ... to 3 p.m. at Coast Dental , located next to Target at 1207 ...
(Date:2/8/2016)... Alexandria, Minn. (PRWEB) , ... February 08, 2016 ... ... introduces the BantamPro L top-load case packer for pouches, bags, and flow wrapped ... designed to help co-packers and specialty product manufacturers step up to semi-automatic or ...
(Date:2/8/2016)... ... February 08, 2016 , ... The ... has selected the latest beneficiary of their ongoing community enrichment program. The current ... in area schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try using ... the health benefits of integrating clay into a daily diet are numerous, as clay ... speaker, Perry A~ has since dedicated her life to learning about the benefits of ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  Echo Therapeutics, Inc. ... company focused on non-invasive continuous glucose monitoring ... announced that it will host a webcast ... 2015 at 9:00 a.m. Eastern Time to ... corporate strategy, advancements in its CGM system, ...
(Date:2/8/2016)... -- http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced ... Equipment Market 2016-2020" report to their offering. ... announced the addition of the "Global Skin ... offering. --> Research and ... of the "Global Skin Protective Equipment Market ...
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint ... November Research Group (NRG),s pharmacovigilance technology services division.  ... consulting services and an Oracle Argus Specialized partner, ... to Life Sciences companies. --> ... expands HighPoint,s life sciences capabilities and provides a ...
Breaking Medicine Technology: